The inhibitory effect of roasted licorice extract on human metastatic breast cancer cell-induced bone destruction

Sun Kyoung Lee, Kwang Kyun Park, Jung Han Yoon Park, Soon Sung Lim, WonYoon Chung

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

The aim of this study was to determine whether the ethanol extract of roasted licorice (rLE) could inhibit breast cancer-mediated bone destruction. rLE treatment reduced the viability of MDA-MB-231 human metastatic breast cancer cells but did not show any cytotoxicity in hFOB1.19 human osteoblastic cells and murine bone marrow-derived macrophages (BMMs). rLE inhibited expression and secretion of receptor activator of nuclear factor κB ligand (RANKL) as well as the mRNA and protein expression of cyclooxygenase-2 in osteoblastic cells exposed to the conditioned medium of breast cancer cells. rLE dramatically inhibited RANKL-induced osteoclastogenesis in BMMs, thereby reducing osteoclast-mediated pit formation. Moreover, treatment with licochalcone A and isoliquiritigenin as the active components, whose contents are increased by the roasting process, remarkably suppressed RANKL-induced osteoclast formation in BMMs, respectively. Furthermore, orally administered rLE substantially blocked tumor growth and bone destruction in mice inoculated with breast cancer cells in the tibiae. Serum levels of tartrate-resistant acid phosphatase and C-terminal cross-linking telopeptide of type I collagen and trabecular bone morphometric parameters were reversed to almost the same levels as the control mice by the rLE treatment. In conclusion, rLE may be a beneficial agent for preventing and treating bone destruction in patients with breast cancer.

Original languageEnglish
Pages (from-to)1776-1783
Number of pages8
JournalPhytotherapy Research
Volume27
Issue number12
DOIs
Publication statusPublished - 2013 Dec 1

Fingerprint

Glycyrrhiza
Breast Neoplasms
Bone and Bones
Macrophages
Osteoclasts
Bone Neoplasms
Bone Development
Cyclooxygenase 2
Cytoplasmic and Nuclear Receptors
Conditioned Culture Medium
Tibia
Osteogenesis
Ethanol
Therapeutics
Ligands
Messenger RNA
Serum

All Science Journal Classification (ASJC) codes

  • Pharmacology

Cite this

Lee, Sun Kyoung ; Park, Kwang Kyun ; Park, Jung Han Yoon ; Lim, Soon Sung ; Chung, WonYoon. / The inhibitory effect of roasted licorice extract on human metastatic breast cancer cell-induced bone destruction. In: Phytotherapy Research. 2013 ; Vol. 27, No. 12. pp. 1776-1783.
@article{129b3a00f3074b94acd9dea59ed40aa1,
title = "The inhibitory effect of roasted licorice extract on human metastatic breast cancer cell-induced bone destruction",
abstract = "The aim of this study was to determine whether the ethanol extract of roasted licorice (rLE) could inhibit breast cancer-mediated bone destruction. rLE treatment reduced the viability of MDA-MB-231 human metastatic breast cancer cells but did not show any cytotoxicity in hFOB1.19 human osteoblastic cells and murine bone marrow-derived macrophages (BMMs). rLE inhibited expression and secretion of receptor activator of nuclear factor κB ligand (RANKL) as well as the mRNA and protein expression of cyclooxygenase-2 in osteoblastic cells exposed to the conditioned medium of breast cancer cells. rLE dramatically inhibited RANKL-induced osteoclastogenesis in BMMs, thereby reducing osteoclast-mediated pit formation. Moreover, treatment with licochalcone A and isoliquiritigenin as the active components, whose contents are increased by the roasting process, remarkably suppressed RANKL-induced osteoclast formation in BMMs, respectively. Furthermore, orally administered rLE substantially blocked tumor growth and bone destruction in mice inoculated with breast cancer cells in the tibiae. Serum levels of tartrate-resistant acid phosphatase and C-terminal cross-linking telopeptide of type I collagen and trabecular bone morphometric parameters were reversed to almost the same levels as the control mice by the rLE treatment. In conclusion, rLE may be a beneficial agent for preventing and treating bone destruction in patients with breast cancer.",
author = "Lee, {Sun Kyoung} and Park, {Kwang Kyun} and Park, {Jung Han Yoon} and Lim, {Soon Sung} and WonYoon Chung",
year = "2013",
month = "12",
day = "1",
doi = "10.1002/ptr.4930",
language = "English",
volume = "27",
pages = "1776--1783",
journal = "Phytotherapy Research",
issn = "0951-418X",
publisher = "John Wiley and Sons Ltd",
number = "12",

}

The inhibitory effect of roasted licorice extract on human metastatic breast cancer cell-induced bone destruction. / Lee, Sun Kyoung; Park, Kwang Kyun; Park, Jung Han Yoon; Lim, Soon Sung; Chung, WonYoon.

In: Phytotherapy Research, Vol. 27, No. 12, 01.12.2013, p. 1776-1783.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The inhibitory effect of roasted licorice extract on human metastatic breast cancer cell-induced bone destruction

AU - Lee, Sun Kyoung

AU - Park, Kwang Kyun

AU - Park, Jung Han Yoon

AU - Lim, Soon Sung

AU - Chung, WonYoon

PY - 2013/12/1

Y1 - 2013/12/1

N2 - The aim of this study was to determine whether the ethanol extract of roasted licorice (rLE) could inhibit breast cancer-mediated bone destruction. rLE treatment reduced the viability of MDA-MB-231 human metastatic breast cancer cells but did not show any cytotoxicity in hFOB1.19 human osteoblastic cells and murine bone marrow-derived macrophages (BMMs). rLE inhibited expression and secretion of receptor activator of nuclear factor κB ligand (RANKL) as well as the mRNA and protein expression of cyclooxygenase-2 in osteoblastic cells exposed to the conditioned medium of breast cancer cells. rLE dramatically inhibited RANKL-induced osteoclastogenesis in BMMs, thereby reducing osteoclast-mediated pit formation. Moreover, treatment with licochalcone A and isoliquiritigenin as the active components, whose contents are increased by the roasting process, remarkably suppressed RANKL-induced osteoclast formation in BMMs, respectively. Furthermore, orally administered rLE substantially blocked tumor growth and bone destruction in mice inoculated with breast cancer cells in the tibiae. Serum levels of tartrate-resistant acid phosphatase and C-terminal cross-linking telopeptide of type I collagen and trabecular bone morphometric parameters were reversed to almost the same levels as the control mice by the rLE treatment. In conclusion, rLE may be a beneficial agent for preventing and treating bone destruction in patients with breast cancer.

AB - The aim of this study was to determine whether the ethanol extract of roasted licorice (rLE) could inhibit breast cancer-mediated bone destruction. rLE treatment reduced the viability of MDA-MB-231 human metastatic breast cancer cells but did not show any cytotoxicity in hFOB1.19 human osteoblastic cells and murine bone marrow-derived macrophages (BMMs). rLE inhibited expression and secretion of receptor activator of nuclear factor κB ligand (RANKL) as well as the mRNA and protein expression of cyclooxygenase-2 in osteoblastic cells exposed to the conditioned medium of breast cancer cells. rLE dramatically inhibited RANKL-induced osteoclastogenesis in BMMs, thereby reducing osteoclast-mediated pit formation. Moreover, treatment with licochalcone A and isoliquiritigenin as the active components, whose contents are increased by the roasting process, remarkably suppressed RANKL-induced osteoclast formation in BMMs, respectively. Furthermore, orally administered rLE substantially blocked tumor growth and bone destruction in mice inoculated with breast cancer cells in the tibiae. Serum levels of tartrate-resistant acid phosphatase and C-terminal cross-linking telopeptide of type I collagen and trabecular bone morphometric parameters were reversed to almost the same levels as the control mice by the rLE treatment. In conclusion, rLE may be a beneficial agent for preventing and treating bone destruction in patients with breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=84890565299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890565299&partnerID=8YFLogxK

U2 - 10.1002/ptr.4930

DO - 10.1002/ptr.4930

M3 - Article

VL - 27

SP - 1776

EP - 1783

JO - Phytotherapy Research

JF - Phytotherapy Research

SN - 0951-418X

IS - 12

ER -